ACE and COVID-19: Studies reported that the use of ACE1 inhibitors/angiotensin-receptor blockers in hypertensive patients with COVID-19 was associated with a lower risk of mortality than those in hypertensive patients who do not use these agents, thus highlighting the safety of these drugs [63,64].